Who is AstrazenecaAstraZeneca: Advancing Health Equity and Innovation in the U.S.
AstraZeneca is a global, science-led biopharmaceutical company committed to delivering life-changing medicines and improving health outcomes. In the United States, the company focuses on addressing health disparities, embracing digital innovation, and fostering collaborations to enhance patient care.
Accelerating Health Equity
Through the “Accelerate Change Together (ACT) on Health Equity” initiative, AstraZeneca is dedicated to transforming healthcare access and outcomes for underserved communities across the U.S. By investing in community-based solutions and partnering with local organizations, the company aims to break down barriers to quality care. AstraZeneca+1AstraZeneca+1
Embracing Digital Health
AstraZeneca is at the forefront of digital health innovation, striving to create patient-centric clinical trials and augment patient outcomes with digital solutions. The launch of Evinova, a health-tech business, exemplifies the company’s commitment to leveraging technology to accelerate innovation in the life sciences sector. AstraZeneca+1AstraZeneca biopharmadive.com
Collaborative Efforts for Better Health
Recognizing the importance of partnerships, AstraZeneca collaborates with healthcare professionals, regulators, and other stakeholders to reimagine healthcare delivery. These collaborations aim to enhance patient experiences and ensure that advancements in medicine are accessible to all.
Commitment to a Healthier Future
AstraZeneca’s dedication to science, innovation, and patient-centric care positions the company as a leader in the U.S. healthcare landscape. Through continuous efforts to improve health equity and embrace digital transformation, AstraZeneca is shaping a healthier future for all Americans.
If you would like this content adapted into different formats, such as infographics, videos, or presentations, to suit the needs of AtiveSite Health, please let me know.
Below is a table of seven of AstraZeneca’s key medicines in the United States, including their generic names, primary indications and most recent U.S. approval dates:
| Brand | Generic Name | Primary Indication | Latest U.S. Approval |
|---|---|---|---|
| Tagrisso | Osimertinib | EGFR-mutated non–small cell lung cancer (stage III post-chemoradiotherapy) | Sept 25, 2024 U.S. Food and Drug Administration; $4.9 B global sales through Q3 2024 Fierce Pharma |
| Imfinzi | Durvalumab | Limited-stage small cell lung cancer (post-chemoradiotherapy) | Dec 4, 2024 U.S. Food and Drug Administration; $3.5 B global sales through Q3 2024 Fierce Pharma |
| Lynparza | Olaparib | BRCA-mutated ovarian and breast cancers | FY 2024 product sales $3.07 B AstraZeneca |
| Farxiga | Dapagliflozin | Type 2 diabetes, heart failure, chronic kidney disease | 2014 (initial); 2024 top-25 global blockbuster (#19) Drug Discovery Trends |
| Calquence | Acalabrutinib | Mantle cell lymphoma (with bendamustine + rituximab) | Jan 16, 2025 U.S. Food and Drug Administration |
| Lokelma | Sodium zirconium cyclosilicate | Hyperkalemia | May 18, 2018 Drugs.com |
| Truqap | Capivasertib (with fulvestrant) | HR-positive/HER2-negative advanced breast cancer | Nov 16, 2023 U.S. Food and Drug Administration |
-
Sales figures (where shown) are global or through Q3 2024, as publicly reported by AstraZeneca and industry trackers Fierce PharmaAstraZeneca.
-
Approval dates reflect the most recent significant FDA nods for expanded or new indications.
Camizestrant, selective estrogen receptor degrader (SERD), oral SERD, ESR1 mutation, hormone receptor–positive breast cancer, HR +/HER2- breast cancer, SERENA-6 trial, phase III clinical trial, progression-free survival benefit, CDK4/6 inhibitor combination, palbociclib, ribociclib, abemaciclib, endocrine resistance, precision medicine, targeted oncology, breast cancer innovation, AstraZeneca oncology pipeline, first-line therapy, next-generation therapy, oral cancer therapy, complete ER antagonist, investigational therapy, patient-centric treatment, cancer research
AstraZeneca, biopharmaceuticals, oncology, cardiovascular, respiratory, immunology, rare diseases, vaccines, COVID-19 vaccine, Vaxzevria, Tagrisso, Imfinzi, Lynparza, Farxiga, Brilinta, Seroquel, Crestor, Evinova, digital health, health equity, clinical trials, R&D, global healthcare, pharmaceutical innovation, Pascal Soriot
